Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AXS-02

Other · developed by Axsome Therapeutics

Phase 3 Most advanced trial (none active)
AXSM Developer
2 Registered trials

What is AXS-02?

AXS-02 is an investigational drug studied in Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy, Osteoarthritis, Knee.

At a glance

Drug type
Other
Therapy area
Musculoskeletal
Developer
Axsome Therapeutics, Inc. (AXSM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02746068 Phase 3 Osteoarthritis, Knee Unknown AXSM
NCT02504008 Phase 3 Complex Regional Pain Syndrome Unknown AXSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Complex Regional Pain SyndromeOsteoarthritis, KneeReflex Sympathetic Dystrophy

More from Axsome Therapeutics

AXS-07 FDA approved Dextromethorphan/Bupropion FDA approved Solriamfetol FDA approved AXS-14 Phase 3

Follow AXSM, the company behind AXS-02

See AXSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AXSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.